Healionics is addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure. Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of occlusion and infection suffered by current devices. We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices: scarring and infection. The company is currently conducting human studies of STARgraft and has 36 patents issued or pending.